Access the Next-Generation of Cancer Diagnostics

One of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease. Next-generation sequencing (NGS) helps respond to these challenges by providing a comprehensive view of the tumor’s genomic profile. Importantly, NGS can detect multiple mutations present at very low levels within the tumor.


Targeted NGS Panels for Myeloid Malignancies
CGI’s unique Myeloid NGS panels provide actionable information for improved diagnosis, prognosis, and risk stratification for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).  Based on the Focus::NGS™ result, each patient can receive the most suitable treatment tailored to their unique cancer.  By personalizing diagnosis and improving risk stratification, the Myeloid NGS panels deliver on the promise of precision medicine.

Myeloid NGS Panel   # of Genes   Indication
Focus::AML 37 Acute Myeloid Leukemia
Focus::MDS 27 Myelodysplastic Syndrome
Focus::MPN 25 Myeloproliferative Neoplasms
Focus::Myeloid 50 Other Myeloid malignancies